Search the site

Dr Hannah Moore was one of WA’s brightest minds chosen to speak at TEDX Perth in November last year, presenting her insights into the power of data in fighting infectious diseases to a sold-out crowd at the Perth Concert Hall.

Does Repeated Influenza Vaccination Constrain Influenza Immune Responses and Protection?

Christopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases

FluBubs: Safety and immunogenicity of Early Quadrivalent Influenza Vaccine

Christopher Tobias Blyth Kollmann MBBS (Hons) DCH FRACP FRCPA PhD PhD, M.D., SFUW Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases;

Moort Vax Waangkiny: Understanding reasons for routine vaccine uptake among Aboriginal children aged <5 years in Perth (Boorloo) metro

Aboriginal children aged younger than 5 years in Perth (Boorloo) have lower vaccine uptake compared to non-Aboriginal children.

Paediatric Active Enhanced Diseases Surveillance (PAEDS)

PAEDS monitors for key vaccine preventable conditions and severe side effects from vaccine in 5 paediatric hospitals in Australia.

Characterisation of invasive Group B Streptococcus in Western Australian infants over a 15-year period

Christopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases

Associate Professor Lea-Ann Kirkham

Co-Head, Bacterial Respiratory Infectious Disease Group; Microbiology Lead, Wesfarmers Centre of Vaccines & Infectious Diseases

Lessons from the first year of the WAIVE study investigating the protective effect of influenza vaccine

Influenza is major cause of paediatric hospitalisation. Influenza vaccine was offered to all children aged 6-59 months resident in Western Australia in 2008

A retrospective population-based cohort study identifying target areas for prevention of acute lower respiratory infections in children

Acute lower respiratory infections (ALRI) are a major cause of hospitalisation in young children

Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.

Background: High incidence and serotype diversity of invasive pneumococcal disease (IPD) in Indigenous children in remote Australia led to rapid introduction of